vs
Pediatrix Medical Group, Inc.（MD）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
Pediatrix Medical Group, Inc.的季度营收约是PROCORE TECHNOLOGIES, INC.的1.4倍（$493.8M vs $359.3M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs -2.5%，领先9.4%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.7% vs -1.7%），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（12.4% vs -0.1%）
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
MD vs PCOR — 直观对比
营收规模更大
MD
是对方的1.4倍
$359.3M
营收增速更快
PCOR
高出17.4%
-1.7%
净利率更高
MD
高出9.4%
-2.5%
两年增速更快
PCOR
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $493.8M | $359.3M |
| 净利润 | $33.7M | $-9.1M |
| 毛利率 | — | 80.1% |
| 营业利润率 | 9.9% | 15.5% |
| 净利率 | 6.8% | -2.5% |
| 营收同比 | -1.7% | 15.7% |
| 净利润同比 | 10.5% | 72.4% |
| 每股收益（稀释后） | $0.40 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDPCOR
| Q1 26 | — | $359.3M | ||
| Q4 25 | $493.8M | $349.1M | ||
| Q3 25 | $492.9M | $338.9M | ||
| Q2 25 | $468.8M | $323.9M | ||
| Q1 25 | $458.4M | $310.6M | ||
| Q4 24 | $502.4M | $302.0M | ||
| Q3 24 | $511.2M | $295.9M | ||
| Q2 24 | $504.3M | $284.3M |
净利润MDPCOR
| Q1 26 | — | $-9.1M | ||
| Q4 25 | $33.7M | $-37.6M | ||
| Q3 25 | $71.7M | $-9.1M | ||
| Q2 25 | $39.3M | $-21.1M | ||
| Q1 25 | $20.7M | $-33.0M | ||
| Q4 24 | $30.5M | $-62.3M | ||
| Q3 24 | $19.4M | $-26.4M | ||
| Q2 24 | $-153.0M | $-6.3M |
毛利率MDPCOR
| Q1 26 | — | 80.1% | ||
| Q4 25 | — | 80.1% | ||
| Q3 25 | — | 79.7% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 79.1% | ||
| Q4 24 | — | 81.2% | ||
| Q3 24 | — | 81.4% | ||
| Q2 24 | — | 83.1% |
营业利润率MDPCOR
| Q1 26 | — | 15.5% | ||
| Q4 25 | 9.9% | -12.3% | ||
| Q3 25 | 13.8% | -4.4% | ||
| Q2 25 | 12.8% | -9.3% | ||
| Q1 25 | 7.0% | -11.7% | ||
| Q4 24 | 7.8% | -21.9% | ||
| Q3 24 | 6.6% | -12.3% | ||
| Q2 24 | -31.3% | -5.2% |
净利率MDPCOR
| Q1 26 | — | -2.5% | ||
| Q4 25 | 6.8% | -10.8% | ||
| Q3 25 | 14.5% | -2.7% | ||
| Q2 25 | 8.4% | -6.5% | ||
| Q1 25 | 4.5% | -10.6% | ||
| Q4 24 | 6.1% | -20.6% | ||
| Q3 24 | 3.8% | -8.9% | ||
| Q2 24 | -30.3% | -2.2% |
每股收益（稀释后）MDPCOR
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.40 | $-0.25 | ||
| Q3 25 | $0.84 | $-0.06 | ||
| Q2 25 | $0.46 | $-0.14 | ||
| Q1 25 | $0.24 | $-0.22 | ||
| Q4 24 | $0.37 | $-0.42 | ||
| Q3 24 | $0.23 | $-0.18 | ||
| Q2 24 | $-1.84 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $375.2M | $386.0M |
| 总债务越低越好 | $570.5M | — |
| 股东权益账面价值 | $865.9M | $1.2B |
| 总资产 | $2.2B | $2.1B |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资MDPCOR
| Q1 26 | — | $386.0M | ||
| Q4 25 | $375.2M | $768.5M | ||
| Q3 25 | $340.1M | $684.0M | ||
| Q2 25 | $224.7M | $620.9M | ||
| Q1 25 | $99.0M | $566.7M | ||
| Q4 24 | $229.9M | $775.4M | ||
| Q3 24 | $103.8M | $756.9M | ||
| Q2 24 | $19.4M | $735.4M |
总债务MDPCOR
| Q1 26 | — | — | ||
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MDPCOR
| Q1 26 | — | $1.2B | ||
| Q4 25 | $865.9M | $1.3B | ||
| Q3 25 | $890.7M | $1.2B | ||
| Q2 25 | $833.8M | $1.2B | ||
| Q1 25 | $789.2M | $1.2B | ||
| Q4 24 | $764.9M | $1.3B | ||
| Q3 24 | $732.5M | $1.3B | ||
| Q2 24 | $706.5M | $1.3B |
总资产MDPCOR
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.2B | $2.2B | ||
| Q3 25 | $2.2B | $2.1B | ||
| Q2 25 | $2.1B | $2.0B | ||
| Q1 25 | $2.0B | $1.9B | ||
| Q4 24 | $2.2B | $2.1B | ||
| Q3 24 | $2.1B | $2.0B | ||
| Q2 24 | $2.0B | $2.0B |
负债/权益比MDPCOR
| Q1 26 | — | — | ||
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.1M | $76.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 3.39× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MDPCOR
| Q1 26 | — | $76.8M | ||
| Q4 25 | $114.1M | $114.9M | ||
| Q3 25 | $137.3M | $88.5M | ||
| Q2 25 | $137.2M | $30.8M | ||
| Q1 25 | $-117.5M | $66.0M | ||
| Q4 24 | $133.0M | $29.1M | ||
| Q3 24 | $91.8M | $39.3M | ||
| Q2 24 | $107.0M | $58.7M |
自由现金流MDPCOR
| Q1 26 | — | — | ||
| Q4 25 | — | $109.2M | ||
| Q3 25 | — | $83.1M | ||
| Q2 25 | — | $27.9M | ||
| Q1 25 | — | $62.0M | ||
| Q4 24 | — | $17.4M | ||
| Q3 24 | — | $35.7M | ||
| Q2 24 | — | $56.8M |
自由现金流率MDPCOR
| Q1 26 | — | — | ||
| Q4 25 | — | 31.3% | ||
| Q3 25 | — | 24.5% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | 20.0% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | 12.1% | ||
| Q2 24 | — | 20.0% |
资本支出强度MDPCOR
| Q1 26 | — | — | ||
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 0.7% |
现金转化率MDPCOR
| Q1 26 | — | — | ||
| Q4 25 | 3.39× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | -5.66× | — | ||
| Q4 24 | 4.36× | — | ||
| Q3 24 | 4.72× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
PCOR
暂无分部数据
